Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03167619
Title Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Duke University

triple-receptor negative breast cancer


Durvalumab + Olaparib


Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.